Pneumococcal Vaccine is a subunit vaccine commercialized by CanSino Biologics, with a leading Phase I program in Streptococcal Pneumonia. According to Globaldata, it is involved in 3 clinical trials, of which 1 was completed, 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Pneumococcal Vaccine’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Pneumococcal Vaccine is expected to reach an annual total of $2 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Pneumococcal Vaccine Overview
Protein-based pneumococcal vaccine is under development for the prevention of streptococcal pneumonia infections. The therapeutic candidate is a serotype-independent protein-based pneumococcal vaccine. It is administered through intramuscular route.
CanSino Biologics Overview
CanSino Biologics is a biopharmaceutical company that develops, manufactures and commercializes pneumococcal, polyvalent conjugate and adenovirus-based recombinant TB vaccines. The company is investigating Ad5-EBOV, an adenovirus type 5 vector, to treat Ebola virus, MCV2 and MCV4 vaccines for the prevention of Neisseria meningitidis bacteria. It is also evaluating DTcP vaccine against pertussis caused after primary vaccination in infants and children and PBPV, PCV13i vaccines, targeting pneumococcal diseases. CanSino Biologics utilizes Adenovirus-based viral vector vaccine, conjugation, formulation and protein structure design and recombinant technology to develop vaccines. The company works in partnership with MC Master University, National Research Council of Canada and Beijing Institute of Biotechnology. CanSino Biologics is headquartered in Tianjin, China.
The company reported revenues of (Renminbi) CNY1,031 million for the fiscal year ended December 2022 (FY2022), a decrease of 76% over FY2021. The operating loss of the company was CNY1,368.7 million in FY2022, compared to an operating profit of CNY1,911.6 million in FY2021. The net loss of the company was CNY909.4 million in FY2022, compared to a net profit of CNY1,914.4 million in FY2021.
For a complete picture of Pneumococcal Vaccine’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.